Faculty of Kinesiology and Recreation Management, University of Manitoba, Winnipeg, Canada; Health, Leisure, and Human Performance Research Institute, University of Manitoba, Winnipeg, Canada; Pan Am Clinic, Winnipeg, Canada.
Department of Human Anatomy and Cell Sciences, University of Manitoba, Winnipeg, Canada; Pan Am Clinic, Winnipeg, Canada.
Nutr Res. 2018 Mar;51:57-66. doi: 10.1016/j.nutres.2017.12.010. Epub 2017 Dec 29.
The study purpose was to evaluate the effectiveness of creatine monohydrate supplementation (20 grams/day for 1 week and then 5 grams/day for 11 weeks) on inflammation (C-reactive protein, interleukin-1β, interleukin-6, s100 A8/A9, and tumor necrosis factor-α) and cartilage degradation (serum cartilage oligomeric matrix protein) in patients with knee osteoarthritis. We hypothesized that supplementing with creatine monohydrate for 12 weeks would lower biomarkers of inflammation and cartilage degradation in patients with knee osteoarthritis when compared to placebo. A total of 18 patients with mild to moderate knee osteoarthritis were recruited and randomized in a double blind fashion to either a creatine supplementation group (N = 9) or a placebo (N = 9). At baseline and after 12 weeks of supplementation patients had inflammatory and cartilage degradation biomarkers measured in the systemic blood. Further, patients completed the Knee injury and Osteoarthritis Outcome (KOOS) questionnaire as well as had their isometric thigh strength evaluated using an isokinetic dynamometer at both time points. Results indicated that there was no difference between the creatine and placebo groups at 12 week follow up in the inflammatory biomarkers measured nor was there any difference between the groups for cartilage degradation (all P>.05). No statistical differences were noted for the KOOS questionnaire subscales or total score (all P>.05). Muscle strength testing indicated a main effect of time for both groups where isometric thigh strength at 0° of knee flexion was lowered significantly (P=.047). No other significant differences were found in the strength data. We conclude that 12 weeks of supplementation with creatine monohydrate does not affect inflammatory biomarkers, cartilage degradation, KOOS scores, or muscle strength in patients with mild to moderate knee osteoarthritis.
本研究旨在评估肌酸一水合物补充剂（20 克/天持续 1 周，然后 5 克/天持续 11 周）对膝骨关节炎患者炎症（C 反应蛋白、白细胞介素-1β、白细胞介素-6、s100A8/A9 和肿瘤坏死因子-α）和软骨降解（血清软骨寡聚基质蛋白）的疗效。我们假设，与安慰剂相比，肌酸一水合物补充 12 周会降低膝骨关节炎患者的炎症和软骨降解生物标志物。共招募了 18 名轻度至中度膝骨关节炎患者，并以双盲方式随机分为肌酸补充组（N=9）或安慰剂组（N=9）。在基线和补充 12 周后，患者在系统血液中测量了炎症和软骨降解生物标志物。此外，患者在这两个时间点都完成了膝关节损伤和骨关节炎结果（KOOS）问卷，以及使用等速测力计评估其等长大腿力量。结果表明，在 12 周的随访中，肌酸组和安慰剂组之间在测量的炎症生物标志物方面没有差异，两组之间在软骨降解方面也没有差异（所有 P>.05）。KOOS 问卷子量表或总分均无统计学差异（所有 P>.05）。肌肉力量测试表明，两组的时间都有主要影响，即膝关节 0°时的等长大腿力量明显降低（P=.047）。在力量数据中没有发现其他显著差异。我们得出结论，补充肌酸一水合物 12 周不会影响轻度至中度膝骨关节炎患者的炎症生物标志物、软骨降解、KOOS 评分或肌肉力量。
